{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-032514","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.047356+00:00","generated_at":"2026-06-04T14:51:24.284737+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Syndax appoints Steven Closter as CCO as Steve Sabus resigns; expects two product launches in 2024","bullets":["Steve Sabus voluntarily resigned as CCO on March 15, 2024 due to personal reasons.","Steven Closter appointed CCO effective March 18; leads commercial strategy for anticipated launches of revumenib and axatilimab.","Closter received base salary $460K, 45% target bonus, option for 150K shares, PRSU of 25K units, and sign-on RSU of 9K units.","Closter brings over 30 years biopharma commercial experience, previously VP at Sunovion/Sumitomo Pharma America and Forest Labs/Allergan.","Company reaffirms on track for two first- and best-in-class product launches in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-032514","json":"https://secwatch.observer/filing/0000950170-24-032514.json","markdown":"https://secwatch.observer/filing/0000950170-24-032514.md","text":"https://secwatch.observer/filing/0000950170-24-032514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024032514/0000950170-24-032514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024032514/sndx-20240315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T14:51:24.284737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bacfb0027f","claim":"Steven Closter was appointed as Chief Commercial Officer at Syndax Pharmaceuticals Inc.","evidence_excerpt":"On March 18, 2024, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steven Closter will join the Company as Chief Commercial Officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024032514/0000950170-24-032514-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"f3d0c15e64","claim":"Steve Sabus resigned as Chief Commercial Officer at Syndax Pharmaceuticals Inc.","evidence_excerpt":"On March 15, 2024, Steve Sabus, the previous Chief Commercial Officer of the Company, notified the Company of his voluntary resignation from his position due to personal reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017024032514/0000950170-24-032514-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}